scispace - formally typeset
M

Manuela Baccarini

Researcher at Max F. Perutz Laboratories

Publications -  90
Citations -  7483

Manuela Baccarini is an academic researcher from Max F. Perutz Laboratories. The author has contributed to research in topics: MAPK/ERK pathway & Kinase. The author has an hindex of 45, co-authored 85 publications receiving 6839 citations. Previous affiliations of Manuela Baccarini include Albert Einstein College of Medicine & Hannover Medical School.

Papers
More filters
Journal ArticleDOI

Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock.

TL;DR: It is reported that mice devoid of the JAK protein tyrosine kinase family member, Tyk2, were resistant to shock induced by high doses of LPS, and IFN-β–null but not STAT1-null mice were also resistant to high dose LPS treatment, suggesting thatTyk2 and IFn-β are essential effectors in LPS induced lethality.
Journal ArticleDOI

RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein.

TL;DR: In this paper, an MST2-dependent effector pathway for RASSF1A proapoptotic signaling was proposed, where the Raf1 proto-oncogene binds to MST 2 to prevent its activation.

RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein.

TL;DR: It is shown that key steps in RASSF1A-induced apoptosis are the disruption of the inhibitory Raf1-MST2 complex by RASSf1A and the concomitant enhancement of MST2 interaction with its substrate, LATS1.
Journal ArticleDOI

Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene

TL;DR: It is reported that c‐raf‐1−/− embryos are growth retarded and die at midgestation with anomalies in the placenta and in the fetal liver, and that effectors distinct from the MEK/ERK cascade must mediate the anti‐apoptotic function of Raf‐1.